Τρίτη 9 Μαΐου 2017

Phase II data of brigantinib for relapsed and metastatic NSCLC released

Data from the pivotal Phase 2 ALTA clinical trial evaluating brigatinib in patients with crizotinib-refractory, anaplastic lymphoma kinase-positive (ALK ) locally advanced or metastatic non-small cell lung cancer (NSCLC) were published in the Journal of...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qVdeQB
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις